Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | AML: new targeted inhibitors as single agents?

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the use of new targeted inhibitors as single agents or in combination with standard intensive or novel non-intensive treatment approaches. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).